

Distinct Chemopreventive Effects of Aspirin in Diffuse and Intestinal-Type Gastric Cancer

Ryota Niikura¹, Yoku Hayakawa¹, Yoshihiro Hirata¹, Mitsuru Konishi¹, Nobumi Suzuki², Sozaburo Ihara^{1,2}, Atsuo Yamada¹, Tetsuo Ushiku³, Mitsuhiro Fujishiro^{1,4}, Masashi Fukayama³, and Kazuhiko Koike¹



Abstract

Introduction: Although aspirin/NSAIDs may have potential preventive effects on several cancers, it remains unclear on gastric cancer. The purpose of this study is to compare the risk of developing gastric cancer and the histologic changes of intestinal metaplasia and neutrophil infiltration, between aspirin/NSAID users and nonusers.

Methods: Using an electronic endoscopy database in two hospitals from 1996 to 2017, we analyzed the data from patients with chronic gastritis who received aspirin or NSAIDs prior to upper gastrointestinal endoscopy. One-to-one propensity score matching was performed to compare the proportion of gastric cancer, intestinal metaplasia, and neutrophil infiltration between these drug users and nonusers.

Results: We analyzed 2,082 aspirin users and 2,082 nonusers as well as 898 NSAID users and 898 nonusers.

Six diffuse-type and 19 intestinal-type gastric cancer, 1,243 intestinal metaplasia, and 1,503 neutrophil infiltration patients were identified. The proportion of diffuse-type gastric cancer (0.05%) was 80% lower in aspirin users compared with the nonusers (0.24%), and there was no case of diffuse-type cancer in patients who took aspirin for more than 2 years. In contrast, intestinal-type gastric cancer incidence was significantly higher in aspirin users (0.72%) compared with nonusers (0.14%). No significant differences in the incidence of gastric cancer were found between NSAID use and nonusers. NSAID use was significantly associated with decreased proportion of neutrophil infiltration compared with nonusers.

Conclusion: Aspirin may have distinct effects between intestinal-type and diffuse-type gastric cancer development. *Cancer Prev Res*; 11(5); 279–86. ©2018 AACR.

Introduction

Although the incidence of gastric cancer in western countries has been decreasing, it remains one of the most common cancers and is one of the leading causes of cancer mortality worldwide (1). *Helicobacter pylori* (*H. pylori*) is the most important carcinogen for gastric cancer. In the stomach, *H. pylori* induces chronic inflammation with a massive infiltration of neutrophils and other immune cells. This is followed by gastric atrophy and intestinal metaplasia and

culminates in the development of gastric cancer through the Correa pathway, a multistep histopathologic cascade. The presence of neutrophil infiltration and intestinal metaplasia in gastric biopsy samples is an independent risk factor for gastric cancer (2, 3). Thus, the inhibition of chronic inflammation and subsequent histopathologic changes may lead to the prevention of gastric cancer.

Aspirin, including buffered and enteric-coated forms, are widely used for the treatment of various types of diseases due to their anti-inflammatory and antiplatelet functions. Aspirin and NSAIDs inhibit inflammatory signals through suppression of cyclooxygenase (Cox) activity and prostaglandin (PG) synthesis (4). Experimentally, Cox inhibition by these drugs may lead to the induction of apoptosis (5) and the inhibition of angiogenesis (6), resulting in an anticarcinogenic effect in several cancer types (7). Indeed, it has been reported that aspirin exhibits a protective effect on colorectal cancer development (8, 9), and several studies have suggested that it may also have a protective effect on gastric cancer development (10–14). However, other observational studies and randomized controlled trials reported a nonsignificant association between aspirin use and the development of gastric cancer or intestinal

¹Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. ²Division of Gastroenterology, The Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan. ³Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. ⁴Department of Endoscopy and Endoscopic Surgery, The University of Tokyo, Tokyo, Japan.

Note: Supplementary data for this article are available at Cancer Prevention Research Online (<http://cancerprevres.aacrjournals.org/>).

Corresponding Author: Yoku Hayakawa, Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 1138655, Japan. Phone: 813-3815-5411; Fax: 813-5800-9801; E-mail: yhayakawa-tyk@umin.ac.jp

doi: 10.1158/1940-6207.CAPR-17-0276

©2018 American Association for Cancer Research.

Niikura et al.

metaplasia; thus, the effect of aspirin or NSAIDs use on gastric carcinogenesis remains undetermined (15, 16).

In previous studies, differences in age, sex, and the presence of comorbidities, and potential confounding factors in aspirin/NSAID users and nonusers were often not appropriately adjusted, which may have led to biased results that influenced the conclusions. These confounding factors include the use of drugs that may alter the background histopathologic status of the patient. To reduce these biases and confounding factors, we performed a propensity score matching analysis to specifically evaluate the protective effect of these drugs on gastric cancer development and compared the risk of gastric cancer, intestinal metaplasia, and neutrophil infiltration between aspirin users and nonusers and between NSAID users and nonusers.

Materials and Methods

Data source

We developed the Gastric Cancer Endoscopy Database of Tokyo University (Tokyo, Japan) and the Institute for Adult Diseases, Asahi Life Foundation (Tokyo, Japan), which is a retrospectively recorded database of 53,143 patients from 1996 to 2017 who underwent upper gastrointestinal endoscopy. This database included the following information: patient characteristics, indications for endoscopy,

endoscopy findings, histologic findings, gastric cancer data, *H. pylori* infection status, and drug use. The indications for upper gastrointestinal endoscopy included gastric cancer surveillance and observed gastrointestinal symptoms. For patients who underwent repeated endoscopies, we used the data from the first examination record.

Study design, setting, and participants

We performed two retrospective cohort analyses using our database during 1996 to 2017. We extracted data from patients who had undergone upper endoscopy for gastric cancer surveillance without a previous 5-year diagnosis of gastric cancer.

We selected a case group who received daily aspirin (100 mg enteric-coated or 81 mg buffered aspirin) for at least 30 days prior to initial upper gastrointestinal endoscopy, and a control group who did not receive aspirin (Fig. 1A). Indications for aspirin use included a history of ischemic heart disease, cerebrovascular disease, and thromboembolism. In another analysis, we selected a case group who received daily NSAIDs, including ibuprofen, indomethacin, indomethacin farnesyl, sulindac, diclofenac sodium, naproxen, etodolac, mefenamic acid, meloxicam, or loxoprofen, for at least 30 days prior to initial upper gastrointestinal endoscopy, and a control group who did not receive NSAIDs (Fig. 1B). We calculated the duration of aspirin and NSAID use as the period between first prescription and last prescription




Figure 1. Study flow chart. **A**, Aspirin use and nonuse group. **B**, NSAID use and nonuse group.

data of drugs. Follow-up period is calculated by measuring the time between first visit and last visit to our hospitals: Median follow-up period was 4.2 years.

The human investigations were performed after approval by an Institutional Review Board at the University of Tokyo and the Institute for Adult Diseases, Asahi Life Foundation and in accordance with an assurance filed with and approved by the Japanese Ministry of Health, Labor and Welfare. Written informed consent from patients was obtained from each subject in accordance with Declaration of Helsinki.

Upper gastrointestinal endoscopy and histologic examination

All upper gastrointestinal endoscopies were performed using an electronic video endoscope (Olympus Optical) by experienced endoscopists. Biopsy was performed to evaluate intestinal metaplasia and neutrophil infiltration for all patients except who could not discontinue antithrombotic drugs such as warfarin, thienopyridine, and direct oral anticoagulants. Biopsy specimens were obtained from two points, the antrum and middle corpus of greater curvature. Gastric cancer was diagnosed by pathologic evaluation of biopsy and/or resected specimens. Diffuse-type gastric cancer was defined by the presence of signet-ring cancer cells. Intestinal metaplasia was diagnosed by the presence of goblet cells, absorptive cells, and cells resembling colonoocytes (17). Neutrophil infiltration was diagnosed by the presence of polymorphonuclear leukocytes in the lamina propria of the gastric mucosa based on a previous report (18). All histologic findings were diagnosed by experienced pathologists. In the case of discordant diagnoses between pathologists, they discussed findings and a consensus was reached.

Outcomes and variables

The primary outcome was the risk of gastric cancer. All gastric cancer cases were diagnosed by upper gastrointestinal endoscopy and confirmed by pathologic examination. The secondary outcome was the risk of diffuse-type gastric cancer, intestinal-type gastric cancer, intestinal metaplasia, and neutrophil infiltration.

We evaluated data on age, sex, comorbidities, *H. pylori* infection status, location of cancer, and cancer stage. Age was categorized into quintiles. Comorbidities were evaluated using the Charlson comorbidity index (19). The *H. pylori* infection status was categorized as "positive," "negative," or "unknown." *H. pylori* status was defined as the latest result from serological testing, a urea breath test, or a stool antigen test.

Statistical analysis

We performed a one-to-one propensity score matching analysis between aspirin users and nonusers and between NSAID users and nonusers using estimated propensity scores from each patient (20). To estimate the propensity

score, we fit a logistic regression model for aspirin and NSAID use as a function of patient demographic factors, including age, sex, 15 comorbidities, and *H. pylori* infection status. We calculated the c-statistic to evaluate the goodness-of-fit. Each aspirin and NSAID user was matched with a nonaspirin or NSAIDs user, respectively. Furthermore, patients were matched to those who had the most similar estimated propensity score on the logit scale within a specified range (≤ 0.2 of the pooled SD of estimated logits) to reduce differences between the two groups.

After propensity matching, we compared the proportions of gastric cancer, diffuse-type gastric cancer, intestinal-type gastric cancer, intestinal metaplasia, and neutrophil infiltration in the aspirin and NSAID use and nonuse groups. Categorical data comparisons between the two groups were performed using the χ^2 test or Fisher exact test as appropriate.

Logistic regression analysis was performed to estimate the OR and 95% confidence interval for the risk of gastric cancer, diffuse-type gastric cancer, intestinal-type gastric cancer, intestinal metaplasia, and neutrophil infiltration in the 2- to 6-year and ≥ 6 -year groups relative to the ≤ 2 -year group in patients with aspirin.

Statistical analyses were performed using SAS software version 9.4 (SAS Institute). $P < 0.05$ was considered to indicate statistical significance.

Results

Aspirin use versus nonuse

A total of 2,082 patients who received aspirin were included. The median duration of aspirin use was 4.9 years. After matching, we selected 2,082 controls who did not use aspirin from 48,026 patients. The c-statistic for goodness-of-fit was 0.932 in the propensity score model. Table 1 shows the patient backgrounds in the unmatched and propensity score-matched groups. Patient distributions were closely balanced between matched groups.

Gastric cancer was observed in 17 patients in the aspirin user group and 8 patients in the nonuser group, and the proportion of gastric cancer between the groups was not significantly different (0.82% vs. 0.38%, $P = 0.071$); the characteristics of gastric cancer cases are shown in Supplementary Table S1. When we analyzed the proportion of intestinal-type and diffuse-type gastric cancers separately, we found that there was an 80% lower relative risk of diffuse-type gastric cancer in the aspirin user group (0.05%) compared with the nonuser group (0.24%), although the difference did not reach statistical significance. In contrast, the proportion of intestinal-type gastric cancer was significantly higher in the aspirin user group (0.72%) compared with that in the nonuser group (0.14%; $P = 0.004$). No significant association was observed between aspirin use and cancer location and stage (Supplementary Table S2). No significant difference was observed in the

Table 1. Baseline characteristics of unmatched and propensity score–matched patients in aspirin user and nonuser groups

	Unmatched		<i>P</i>	Propensity score matched		<i>P</i>
	Aspirin use <i>n</i> = 2,083 (%)	Nonuser <i>n</i> = 48,026 (%)		Aspirin use <i>n</i> = 2,082 (%)	Nonuser <i>n</i> = 2,082 (%)	
Age, years						
<50	168 (8.07)	10,205 (21.25)	<0.001	168 (8.07)	144 (6.92)	0.184
50–60	179 (8.59)	9,607 (20.00)		179 (8.60)	190 (9.13)	
60–70	557 (26.74)	13,853 (28.84)		556 (26.71)	586 (28.15)	
70–80	852 (40.90)	11,018 (22.94)		852 (40.92)	877 (42.12)	
≥80	327 (15.70)	3,343 (6.96)		327 (15.71)	285 (13.69)	
Sex, male	1,380 (66.25)	27,075 (56.38)	<0.001	1,380 (66.28)	1,374 (65.99)	0.844
Comorbidities						
Ischemic heart disease	1,478 (70.96)	4,374 (9.11)	<0.001	1,477 (70.94)	1,493 (71.71)	0.584
Chronic heart failure	1,514 (72.68)	5,803 (12.08)	<0.001	1,513 (72.67)	1,518 (72.91)	0.862
Peripheral vascular disease	501 (24.05)	1,921 (4.00)	<0.001	500 (24.02)	461 (22.14)	0.151
Cerebrovascular disease	681 (32.69)	2,020 (4.21)	<0.001	681 (32.71)	668 (32.08)	0.667
Dementia	126 (6.05)	754 (1.57)	<0.001	126 (6.05)	120 (5.76)	0.693
COPD	134 (6.43)	1,017 (2.12)	<0.001	134 (6.44)	132 (6.34)	0.899
Collagen diseases	248 (11.91)	2,636 (5.49)	<0.001	248 (11.91)	261 (12.54)	0.539
Peptic ulcers	1,109 (53.24)	13,628 (28.38)	<0.001	1,108 (53.22)	1,147 (55.09)	0.225
Diabetes	1,616 (77.58)	12,998 (27.06)	<0.001	1,615 (77.57)	1,657 (79.59)	0.113
Chronic kidney disease	314 (15.07)	1,123 (2.34)	<0.001	313 (15.03)	293 (14.07)	0.379
Hemiplegia or paraplegia	137 (6.58)	1,090 (2.27)	<0.001	137 (6.58)	115 (5.52)	0.153
Leukemia	44 (2.11)	363 (0.76)	<0.001	44 (2.11)	49 (2.35)	0.600
Malignant lymphoma	91 (4.37)	1,331 (2.77)	<0.001	91 (4.37)	90 (4.32)	0.939
Liver cirrhosis	72 (3.46)	2,279 (4.75)	0.007	72 (3.46)	73 (3.51)	0.933
AIDS	4 (0.19)	78 (0.16)	0.743	4 (0.19)	1 (0.05)	0.180
<i>H. pylori</i> infection status						
Negative	55 (2.64)	1,671 (3.48)	<0.001	55 (2.64)	69 (3.31)	0.408
Positive	405 (19.44)	6,030 (12.56)		405 (19.45)	392 (18.83)	
Unknown	1,623 (77.92)	40,325 (83.96)		1,622 (77.91)	1,621 (77.86)	

NOTE: Bold indicates statistical significance ($P < 0.05$).

Abbreviations: AIDS, acquired immunodeficiency syndrome; COPD, chronic obstructive pulmonary disease.

proportion of intestinal metaplasia (40.44% vs. 41.61%) and neutrophil infiltration (49.71% vs. 49.86%) between the two groups (Table 2). No significant association was observed between the duration of aspirin use and gastric cancer, intestinal metaplasia, and neutrophil infiltration in patients with aspirin; however, it is noteworthy that no diffuse-type cancer was observed in patients who received aspirin for more than 2 years (Supplementary Table S3).

NSAID use versus nonuse

We included 898 patients who received NSAIDs and selected 867 controls who did not receive NSAIDs from 49,211 patients using one-to-one propensity score matching

(the *c*-statistic of the model was 0.932). Patient distributions were closely balanced between the two groups (Table 3). The median duration of NSAID use was 0.3 years.

No significant differences were observed in the proportions of gastric cancer (0% vs. 0.33%) and intestinal metaplasia (42.81% vs. 39.79%) between NSAID users and nonusers, whereas NSAID use was significantly associated with decreased proportion of neutrophil infiltration in the antrum (30.86% vs. 36.38%, $P = 0.015$) compared with nonusers (Table 4). No significant association was observed between aspirin use and cancer location and stage (Supplementary Table S4).

Discussion

We performed a propensity score matching analysis and found different effects by aspirin on intestinal-type and diffuse-type gastric cancers. It has been suggested that aspirin and other NSAIDs may prevent gastrointestinal cancers, including gastric cancer (14, 16, 21). Cox-2 expression, which could be suppressed by aspirin and NSAIDs, is often upregulated in inflamed gastrointestinal mucosa and may promote epithelial cell proliferation and carcinogenesis (22–24). Indeed, Cox-2 overexpression induces gastric cancer development, and anti-inflammatory drugs have been found to inhibit gastric cancer progression in several mouse models (3, 25–29). Thus, a potential chemopreventive approach to inhibit gastric cancer could involve the

Table 2. Gastric cancer, intestinal metaplasia, and neutrophil infiltration in propensity score–matched patients with aspirin

	Aspirin use <i>n</i> = 2,082 (%)	Nonuser <i>n</i> = 2,082 (%)	<i>P</i>
Gastric cancer	17 (0.82)	8 (0.38)	0.071
Diffuse-type	1 (0.05)	5 (0.24)	0.218
Intestinal-type	16 (0.77)	3 (0.14)	0.004
Intestinal metaplasia ^{a,b}	628 (40.44)	615 (41.61)	0.512
Antrum	524 (33.63)	529 (35.70)	0.232
Corpus	248 (15.69)	219 (14.80)	0.494
Neutrophil infiltration ^{a,b}	770 (49.71)	733 (49.86)	0.932
Antrum	540 (34.82)	532 (36.02)	0.489
Corpus	675 (42.94)	636 (43.12)	0.920

NOTE: Bold indicates statistical significance ($P < 0.05$).^aAllows duplicated.^bIncludes missing data.

Table 3. Baseline characteristics of unmatched and propensity score–matched patients in NSAID user and nonuser groups

	Unmatched		<i>P</i>	Propensity score matched		<i>P</i>
	NSAIDs use <i>n</i> = 898 (%)	Nonuse <i>n</i> = 49,211 (%)		NSAID use <i>n</i> = 898 (%)	Nonuse <i>n</i> = 898 (%)	
Age, years						
<50	161 (17.93)	10,212 (20.75)	<0.001	161 (17.93)	146 (16.26)	0.534
50–60	179 (19.33)	9,607 (19.52)		179 (19.93)	160 (17.82)	
60–70	304 (33.85)	14,106 (28.66)		304 (33.85)	331 (36.86)	
70–80	228 (25.39)	11,642 (23.66)		228 (25.39)	232 (25.84)	
≥80	26 (2.90)	3,644 (7.40)		26 (2.90)	29 (3.23)	
Sex, male	449 (50.00)	28,006 (56.91)	<0.001	449 (50.00)	445 (49.55)	0.850
Comorbidities						
Ischemic heart disease	227 (25.28)	5,625 (11.43)	<0.001	227 (25.28)	249 (27.73)	0.240
Chronic heart failure	319 (35.52)	6,998 (14.22)	<0.001	319 (35.52)	325 (36.19)	0.768
Peripheral vascular disease	111 (12.36)	2,311 (4.70)	<0.001	111 (12.36)	103 (11.47)	0.560
Cerebrovascular disease	130 (14.48)	2,571 (5.22)	<0.001	130 (14.48)	128 (14.25)	0.893
Dementia	36 (4.01)	844 (1.72)	<0.001	36 (4.01)	30 (3.34)	0.452
COPD	58 (6.46)	1,093 (2.22)	<0.001	58 (6.46)	60 (6.68)	0.850
Collagen diseases	198 (22.05)	2,686 (5.46)	<0.001	198 (22.05)	190 (21.16)	0.647
Peptic ulcers	625 (69.60)	14,112 (28.68)	<0.001	625 (69.60)	627 (69.82)	0.918
Diabetes	568 (62.35)	14,046 (28.54)	<0.001	568 (63.25)	573 (63.81)	0.806
Chronic kidney disease	30 (3.34)	1,407 (2.86)	0.391	30 (3.34)	24 (2.67)	0.407
Hemiplegia or paraplegia	63 (7.02)	1,164 (2.37)	<0.001	63 (7.02)	63 (7.02)	1.000
Leukemia	13 (1.45)	394 (0.80)	0.032	13 (1.45)	12 (1.34)	0.840
Malignant lymphoma	82 (9.13)	1,340 (2.72)	<0.001	82 (9.13)	81 (9.02)	0.935
Liver cirrhosis	98 (10.91)	2,253 (4.58)	<0.001	98 (10.91)	93 (10.36)	0.702
AIDS	3 (0.33)	79 (0.16)	0.202	3 (0.33)	2 (0.22)	1.000
<i>H. pylori</i> infection status						
Negative	169 (18.82)	1,557 (3.16)	<0.001	169 (18.82)	172 (19.15)	0.981
Positive	667 (74.28)	5,768 (11.72)		667 (74.28)	665 (74.05)	
Unknown	62 (6.90)	41,886 (85.12)		62 (6.90)	61 (6.79)	

NOTE: Bold indicates statistical significance ($P < 0.05$).

Abbreviations: AIDS, acquired immunodeficiency syndrome; COPD, chronic obstructive pulmonary disease.

suppression of the Cox/Pg pathway by aspirin or NSAIDs. However, our current results showed that aspirin use increased the risk of intestinal-type gastric cancer unexpectedly. In contrast, long-term (>2 years) aspirin use may suppress diffuse-type gastric cancer development, suggesting that chemopreventive effects by aspirin might be specific for this type of histologic cancer.

The pathogenesis of diffuse-type and intestinal-type gastric cancers is quite different. Intestinal-type gastric cancers usually develop through the Correa pathway and are found in the atrophic and metaplastic stomach after long-term *H. pylori* infection. In contrast, diffuse-type cancers sometimes arise even in younger patients without *H. pylori* infection. On a molecular level, approximately

half of intestinal-type gastric cancer cases are characterized by catastrophic chromosomal instability, with frequent mutations in the *TP53* gene (1). Microsatellite instability–related cancers and EBV-related immunologic type cancers are also part of a subset of intestinal-type cancers with characteristic gene mutation signatures. In contrast, the majority of diffuse-type gastric cancers do not have evident genetic or chromosomal alterations and are therefore classified as "genome stable" type. Thus, it is not surprising that aspirin/NSAIDs may have distinct effects on these two subtypes. In addition, although the presence of intestinal metaplasia is a significant risk factor for intestinal-type gastric cancer, it is uncertain whether intestinal metaplasia is a direct precursor of gastric cancer. Thus, it would be possible that the developmental mechanisms of metaplasia and gastric cancer are distinct; thus, the effects by aspirin can be different between these two, as seen in our current analysis.

Findings in humans and mice strongly suggest that loss of E-cadherin expression or *CDH1* gene mutations are key triggers of the production of signet-ring cancer cells, but accumulating evidence suggests that chronic inflammation, with or without additional genetic events, may be required for progression to invasive diffuse-type cancer (2–4, 30, 31). Although we would propose the possibility that long-term use of aspirin may prevent diffuse-type cancer by suppressing chronic inflammatory responses in the stomach, further study is required in a larger and longer cohort (32).

Table 4. Gastric cancer, intestinal metaplasia, and neutrophil infiltration in propensity score–matched patients with NSAIDs

	NSAID use <i>n</i> = 898 (%)	Nonuse <i>n</i> = 898 (%)	<i>P</i>
Gastric cancer	0 (0)	3 (0.33)	0.250
Diffuse-type	0 (0)	1 (0.11)	1.000
Intestinal-type	0 (0)	2 (0.22)	0.500
Intestinal metaplasia ^{a,b}	367 (42.58)	344 (39.91)	0.261
Antrum	311 (36.00)	293 (33.79)	0.337
Corpus	132 (15.12)	121 (14.04)	0.523
Neutrophil infiltration ^{a,b}	388 (45.27)	428 (49.94)	0.053
Antrum	266 (30.86)	314 (36.38)	0.015
Corpus	351 (40.72)	367 (42.82)	0.376

NOTE: Bold indicates statistical significance ($P < 0.05$).^aAllows duplicated.^bIncludes missing data.

Previous randomized controlled trials failed to prevent the development of gastric cancer in patients with chronic gastritis by long term use of Cox-2 inhibitors (33, 34). *H. pylori* sometimes disappears in stomachs with advanced atrophy, but gastric cancers, in particular intestinal-type cancers, can still develop without active *H. pylori* infection (35). In these cases, genetic mutations and epigenetic changes may play more important roles for cancer progression than inflammatory signals, such as the Cox/Pg pathway (32). Our current results showed an inverse relationship between aspirin use and intestinal-type cancer risk. Given that aspirin has apparent effects on mucosal damage in the stomach, such mucosal injury might influence epithelial proliferation and transformation; however, further validation and elucidation of the underlying mechanisms are warranted.

Recently, a retrospective epidemiologic study reported that long-term proton pump inhibitor (PPI) was significantly associated with increased risk of gastric cancer compared with non-PPI use, in patients after *H. pylori* eradication (36). In fact, the proportion of PPI users in aspirin users was higher (32.7 %) than that in aspirin nonusers (4.3%). Thus, we performed additional propensity score matching analysis to evaluate the effect by PPI on gastric cancer. Unlike the previous report (36), PPI use was not associated with gastric cancer, intestinal metaplasia, and neutrophil infiltration (Supplementary Tables S5 and S6). Nevertheless, we do not exclude the possibility that the greater proportion of PPI users in aspirin use group might affect the increase of intestinal-type gastric cancer cases in this group. It is likely that the effect by PPI in gastric cancer development may be restricted in *H. pylori*-eradicated patients; thus, further analysis with detailed information of *H. pylori* status is required to evaluate an exact association between PPI use and gastric carcinogenesis.

Our study had several strengths. We are the first to perform propensity score matching for studying the association between aspirin/NSAIDs and gastric cancer, by following >50,000 patients who received upper endoscopy over 10 years in two separate hospitals. We also included detailed histopathologic findings in our analysis, such as histologic type of cancers and the presence of intestinal metaplasia and neutrophil infiltration. However, our study also had several limitations. The duration of aspirin/NSAID use was relatively short compared with previous studies. Previous observational studies reported that patients who took aspirin for more than 5 years had lower relative odds and HRs of gastric cancer compared with those that did not take aspirin (14, 16). However, the median duration of aspirin and NSAID use in our cohort was 4.9 and 0.3 years, and this may have affected our statistics to evaluate a protective effect of aspirin/NSAIDs on gastric cancer development. In addition, there is a possibility that aspirin/NSAIDs may be prescribed from

other hospitals, or that these drugs are used as off-prescription drugs that we cannot include in our database. However, all types of enteric-coated aspirin are restricted to prescriptional use and not commercially available in Japan. Thus, there is limited chance of off-prescription use of aspirin. Furthermore, the number of gastric cancer events was relatively small, which may lead to statistically insignificant results. Finally, we included data from patients with unknown *H. pylori* status.

In conclusion, aspirin/NSAID use may affect the development of gastric cancers, but it should be validated in future comprehensive cohort or randomized control studies.

Disclosure of Potential Conflicts of Interest

M. Fujishiro reports receiving commercial research grants from EA Pharma Co., HOYA-Pentax Co., and Takeda Pharmaceutical Co., has received speakers bureau honoraria from AstraZeneca Pharmaceuticals, Daiichi-Sankyo Co., Takeda Pharmaceutical Co., and Zeria Pharmaceutical Co. No potential conflicts were disclosed by the other authors.

Disclaimer

The funders had no role in the design of the study, data collection and analysis, decision to publish, or preparation of the manuscript.

Authors' Contributions

Conception and design: R. Niikura, Y. Hayakawa
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Y. Hayakawa, Y. Hirata, M. Konishi, N. Suzuki, S. Ihara, T. Ushiku, M. Fujishiro, M. Fukayama
Analysis and interpretation of data (e.g., statistical analysis, bio-statistics, computational analysis): R. Niikura, Y. Hayakawa, Y. Hirata, M. Konishi
Writing, review, and/or revision of the manuscript: R. Niikura, Y. Hayakawa, Y. Hirata, A. Yamada, M. Fujishiro
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): R. Niikura, M. Fujishiro
Study supervision: Y. Hayakawa, A. Yamada, K. Koike

Acknowledgments

The authors thank Tomohiro Shinozaki of Department of Biostatistics, School of Public Health, Graduate School of Medicine, The University of Tokyo for his help with the statistical analyses. This study was supported by the KAKENHI Grant-in-Aid for Scientific Research, 17K15928 (R.Niikura), 16H06749 and 17H05081 (Y.Hayakawa.), P-CREATE from AMED, the Mitsubishi Foundation, Natural Sciences, the research grant of Astellas Foundation for Research on Metabolic Disorders, the Yasuda Medical Foundation, and the Advanced Research and Development Programs for Medical Innovation (PRIME) (Y. Hayakawa.).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 28, 2017; revised December 10, 2017; accepted February 2, 2018; published first February 16, 2018.

References

1. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* 2014;513:202–9.
2. Hayakawa Y, Fox JG, Wang TC. The origins of gastric cancer from gastric stem cells: Lessons from mouse models. *Cell Mol Gastroenterol Hepatol* 2017;3:331–8.
3. Hayakawa Y, Ariyama H, Stancikova J, Sakitani K, Asfaha S, Renz BW, et al. Mist1 expressing gastric stem cells maintain the normal and neoplastic gastric epithelium and are supported by a perivascular stem cell niche. *Cancer Cell* 2015;28:800–14.
4. Shimada S, Mimata A, Sekine M, Mogushi K, Akiyama Y, Fukamachi H, et al. Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. *Gut* 2012;61:344–53.
5. Shiff SJ, Rigas B. Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. *Gastroenterology* 1997;113:1992–8.
6. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh JJ, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. *Nat Med* 1999;5:1418–23.
7. Tsuji S, Kawano S, Sawaoka H, Takei Y, Kobayashi I, Nagano K, et al. Evidences for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines. *Prostaglandins Leukot Essent Fatty Acids* 1996;55:179–83.
8. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. *JAMA* 2005;294:914–23.
9. Flossmann E, Rothwell PM, British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. *Lancet* 2007;369:1603–13.
10. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. *Helicobacter pylori* eradication to prevent gastric cancer in a high-risk region of china: A randomized controlled trial. *JAMA* 2004;291:187–94.
11. Abnet CC, Freedman ND, Kamangar F, Leitzmann MF, Hollenbeck AR, Schatzkin A. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. *Br J Cancer* 2009;100:551–7.
12. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. *J Natl Cancer Inst* 2003;95:1784–91.
13. Fortuny J, Johnson CC, Bohlke K, Chow WH, Hart G, Kucera G, et al. Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers. *Clin. Gastroenterol. Hepatol* 2007;5:1154–9.
14. Duan L, Wu AH, Sullivan-Halley J, Bernstein L. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles county. *Cancer Epidemiol Biomarkers Prev* 2008;17:126–34.
15. Lindblad M, Lagergren J, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. *Cancer Epidemiol Biomarkers Prev* 2005;14:444–50.
16. Epplein M, Nomura AM, Wilkens LR, Henderson BE, Kolonel LN. Nonsteroidal antiinflammatory drugs and risk of gastric adenocarcinoma: The Multiethnic Cohort Study. *Am J Epidemiol* 2009;170:507–14.
17. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The Updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. *Am J Surg Pathol* 1996;20:1161–81.
18. Sakitani K, Hirata Y, Watabe H, Yamada A, Sugimoto T, Yamaji Y, et al. Gastric cancer risk according to the distribution of intestinal metaplasia and neutrophil infiltration. *J Gastroenterol Hepatol* 2011;26:1570–5.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373–83.
20. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. *Stat Med* 1998;17:2265–81.
21. Hamada T, Cao Y, Qian ZR, Masugi Y, Nowak JA, Yang J, et al. Aspirin use and colorectal cancer survival according to tumor CD274 (programmed cell death 1 ligand 1) expression status. *J Clin Oncol* 2017;35:1836–44.
22. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. *Cancer Res* 1997;57:1276–80.
23. Murata H, Kawano S, Tsuji S, Tsuji M, Sawaoka H, Kimura Y, et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. *Am J Gastroenterol* 1999;94:451–5.
24. Yamamoto H, Itoh F, Fukushima H, Hinoda Y, Imai K. Overexpression of cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite instability. *Int J Cancer* 1999;84:400–3.
25. Buller NV, Rosekrans SL, Metcalfe C, Heijmans J, van Dop WA, Fessler E, et al. Stromal indian hedgehog signaling is required for intestinal adenoma formation in mice. *Gastroenterology* 2015;148:170–80.
26. Mao J, Ligon KL, Rakhlin EY, Thayer SP, Bronson RT, Rowitch D, et al. A novel somatic mouse model to survey tumorigenic potential applied to the hedgehog pathway. *Cancer Res* 2006;66:10171–8.
27. van Dop WA, Heijmans J, Buller NV, Snoek SA, Rosekrans SL, Wassenberg EA, et al. Loss of Indian hedgehog activates multiple aspects of a wound healing response in the mouse intestine. *Gastroenterology* 2010;139:1665–76.
28. Haramis AP, Begthel H, van den Born M, van Es J, Jonkheer S, Offerhaus GJ, et al. De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine. *Science* 2004;303:1684–6.
29. Oshima H, Oshima M, Inaba K, Taketo MM. Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. *EMBO J* 2004;23:1669–78.
30. Humar B, Blair V, Charlton A, More H, Martin I, Guilford P. E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man. *Cancer Res* 2009;69:2050–6.
31. Horiuchi Y, Fujisaki J, Yamamoto N, Shimizu T, Miyamoto Y, Tomida H, et al. Biological behavior of the intramucosal *Helicobacter pylori*-negative undifferentiated-type early gastric cancer: comparison with *helicobacter pylori*-positive early gastric cancer. *Gastric Cancer* 2016;19:160–5.
32. Hayakawa Y, Sethi N, Sepulveda AR, Bass AJ, Wang TC. Oesophageal adenocarcinoma and gastric cancer: should we mind the gap? *Nat Rev Cancer* 2016;16:305–18.

Niikura et al.

33. Leung WK, Ng EK, Chan FK, Chan WY, Chan KF, Auyeung AC, et al. Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial. *Clin. Cancer Res* 2006;12:4766-72.
34. Wong BC, Zhang L, Ma JL, Pan KF, Li JY, Shen L, et al. Effects of selective COX-2 inhibitor and *Helicobacter pylori* eradication on precancerous gastric lesions. *Gut* 2012;61:812-8.
35. Osborn JF, Cattaruzza MS, Ferri AM, De Angelis F, Renzi D, Marani A, et al. How long will it take to reduce gastric cancer incidence by eradicating *helicobacter pylori* infection? *Cancer Prev Res* 2013;6:695-700.
36. Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for *Helicobacter pylori*: a population-based study. *Gut* 2018;67:28-35.

Cancer Prevention Research

Distinct Chemopreventive Effects of Aspirin in Diffuse and Intestinal-Type Gastric Cancer

Ryota Niikura, Yoku Hayakawa, Yoshihiro Hirata, et al.

Cancer Prev Res 2018;11:279-286. Published OnlineFirst February 16, 2018.

Updated version	Access the most recent version of this article at: doi: 10.1158/1940-6207.CAPR-17-0276
Supplementary Material	Access the most recent supplemental material at: http://cancerpreventionresearch.aacrjournals.org/content/suppl/2018/02/16/1940-6207.CAPR-17-0276.DC1

Cited articles	This article cites 36 articles, 11 of which you can access for free at: http://cancerpreventionresearch.aacrjournals.org/content/11/5/279.full#ref-list-1
-----------------------	--

Citing articles	This article has been cited by 1 HighWire-hosted articles. Access the articles at: http://cancerpreventionresearch.aacrjournals.org/content/11/5/279.full#related-urls
------------------------	---

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
----------------------	--

Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org .
-----------------------------------	--

Permissions	To request permission to re-use all or part of this article, use this link http://cancerpreventionresearch.aacrjournals.org/content/11/5/279 . Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.
--------------------	--